Dogwood Therapeutics (DWTX) Competitors $5.08 +0.32 (+6.72%) Closing price 07/14/2025 04:00 PM EasternExtended Trading$4.97 -0.11 (-2.24%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock DWTX vs. XLO, MRSN, LTRN, CLNN, LVTX, TELO, KZR, RNTX, KALA, and OKURShould you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include Xilio Therapeutics (XLO), Mersana Therapeutics (MRSN), Lantern Pharma (LTRN), Clene (CLNN), LAVA Therapeutics (LVTX), Telomir Pharmaceuticals (TELO), Kezar Life Sciences (KZR), Rein Therapeutics (RNTX), KALA BIO (KALA), and OnKure Therapeutics (OKUR). These companies are all part of the "pharmaceutical products" industry. Dogwood Therapeutics vs. Its Competitors Xilio Therapeutics Mersana Therapeutics Lantern Pharma Clene LAVA Therapeutics Telomir Pharmaceuticals Kezar Life Sciences Rein Therapeutics KALA BIO OnKure Therapeutics Dogwood Therapeutics (NASDAQ:DWTX) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk. Do analysts recommend DWTX or XLO? Dogwood Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 96.85%. Xilio Therapeutics has a consensus price target of $4.00, indicating a potential upside of 440.83%. Given Xilio Therapeutics' higher possible upside, analysts clearly believe Xilio Therapeutics is more favorable than Dogwood Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dogwood Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, DWTX or XLO? Dogwood Therapeutics has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDogwood TherapeuticsN/AN/A-$12.35M-$18.04-0.28Xilio Therapeutics$9.27M4.13-$58.24M-$0.84-0.88 Do insiders and institutionals believe in DWTX or XLO? 9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 3.9% of Dogwood Therapeutics shares are owned by insiders. Comparatively, 5.2% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, DWTX or XLO? Dogwood Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.15, suggesting that its share price is 115% less volatile than the S&P 500. Is DWTX or XLO more profitable? Dogwood Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -585.54%. Dogwood Therapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dogwood TherapeuticsN/A N/A -34.74% Xilio Therapeutics -585.54%-262.69%-64.01% Does the media favor DWTX or XLO? In the previous week, Dogwood Therapeutics had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 2 mentions for Dogwood Therapeutics and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.89 beat Dogwood Therapeutics' score of 0.94 indicating that Xilio Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Dogwood Therapeutics Positive Xilio Therapeutics Very Positive SummaryDogwood Therapeutics beats Xilio Therapeutics on 7 of the 13 factors compared between the two stocks. Get Dogwood Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DWTX vs. The Competition Export to ExcelMetricDogwood TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.71M$2.95B$5.54B$9.14BDividend YieldN/A2.43%5.01%4.00%P/E Ratio-0.2821.1628.6919.45Price / SalesN/A184.72372.4779.78Price / CashN/A41.0524.7227.47Price / Book-0.677.758.215.58Net Income-$12.35M-$55.05M$3.19B$252.81M7 Day Performance4.96%9.69%3.60%2.11%1 Month Performance9.25%13.80%9.61%11.87%1 Year PerformanceN/A3.55%30.04%16.61% Dogwood Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DWTXDogwood Therapeutics1.8943 of 5 stars$5.08+6.7%$10.00+96.9%N/A$9.71MN/A-0.285XLOXilio Therapeutics2.925 of 5 stars$0.70+0.2%$4.00+472.0%-27.5%$36.14M$6.34M-0.8370Positive NewsMRSNMersana Therapeutics4.1921 of 5 stars$0.30+5.1%$5.20+1,608.8%-83.5%$36.08M$40.50M-0.52150Positive NewsGap UpLTRNLantern Pharma3.14 of 5 stars$3.15-3.1%$25.00+693.7%-9.7%$35.05MN/A-1.7120Positive NewsHigh Trading VolumeCLNNClene3.6227 of 5 stars$3.87-0.8%$40.00+933.6%-29.0%$35.03M$340K-0.96100LVTXLAVA Therapeutics2.2246 of 5 stars$1.32flat$3.17+139.9%-20.9%$34.72M$11.98M-1.2760Positive NewsTELOTelomir Pharmaceuticals3.5883 of 5 stars$1.15flat$15.00+1,204.3%-71.7%$34.23MN/A-2.741Positive NewsKZRKezar Life Sciences4.0757 of 5 stars$4.55-0.7%$39.50+768.1%-28.1%$33.46M$7M-0.4260RNTXRein TherapeuticsN/A$1.54+2.0%N/AN/A$33.45MN/A-0.549Positive NewsGap DownKALAKALA BIO3.9487 of 5 stars$5.28+3.5%$13.50+155.7%-23.8%$32.91M$3.89M-0.6430News CoverageAnalyst UpgradeGap UpOKUROnKure Therapeutics3.6408 of 5 stars$2.39+0.4%$32.33+1,252.9%N/A$32.15MN/A-0.45N/APositive News Related Companies and Tools Related Companies XLO Alternatives MRSN Alternatives LTRN Alternatives CLNN Alternatives LVTX Alternatives TELO Alternatives KZR Alternatives RNTX Alternatives KALA Alternatives OKUR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DWTX) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DWTX Stock Alerts